This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ilona Slusker Shternfeld, MD; Jacques G. H. Lasudry, MD; Richard J. Chappell, PhD; Soesiawati R. Darjatmoko, MS; Daniel M. Albert, MD

Arch Ophthalmol. 1996;114(11):1396-1401.

Abstract
Objective
To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D₃ analogue in β-luteinizing hormone-Tag (LHβ-Tag) transgenic mice with heritable retinoblastoma.

Methods
Forty-two mice (8-10 weeks old), randomly assigned to experimental (n=21) or control (n=21) groups, received intraperitoneal injections of 0.05 µg of 1,25-dihydroxy-16-ene-23-yne-D₃ in 0.5-mL mineral oil vehicle (experimental group) or 0.5 mL of mineral oil vehicle (control group) for 5 weeks. One experimental and 3 control animals died of injection-related trauma. Eyes were enucleated 1 week after treatment and were examined histologically in a masked fashion.

Results
All experimental and control animals showed evidence of tumor. The tumors in the experimental mice showed a significantly smaller cross-sectional area (0.88±0.08 mm²) compared with that in the control mice (1.12 ±0.12 mm²) (P=.02). All mice completed the treatment and showed no clinical evidence of toxic effects.

Conclusions
Tumors in transgenic mice with retinoblastoma treated with 1,25(OH)₂-16-ene-23-yne-D₃ showed a 21% smaller cross-sectional area compared with that in the control mice, without producing clinically apparent toxic effects. This compound may be useful as adjunctive therapy in the treatment of retinoblastoma.

Author Affiliations
From the Departments of Ophthalmology and Visual Sciences (Drs Shternfeld, Lasudry, and Albert and Ms Darjatmoko) and Biostatistics and Statistics (Dr Chappell), University of Wisconsin Medical School, Madison. The authors do not have any commercial or proprietary interest in 1,25(OH)2-16-ene-23-yne-D3 and have not received payment and acted as consultants or evaluators for Hoffmann-LaRoche for 1,25(OH)2-16-ene-23-yne-D3.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Calcitriol Is a Potent Inhibitor of Retinal Neovascularization
Albert et al.
IOVS 2007;48:2327-2334.
ABSTRACT | FULL TEXT  

Effectiveness of Vitamin D Analogues in Treating Large Tumors and During Prolonged Use in Murine Retinoblastoma Models
Albert et al.
Arch Ophthalmol 2004;122:1357-1362.
ABSTRACT | FULL TEXT  

Vitamin D Analogues Increase p53, p21, and Apoptosis in a Xenograft Model of Human Retinoblastoma
Audo et al.
IOVS 2003;44:4192-4199.
ABSTRACT | FULL TEXT  

Toxicity and Dose-Response Studies of 1{alpha}-Hydroxyvitamin D2 in a Retinoblastoma Xenograft Model
Grostern et al.
Arch Ophthalmol 2002;120:607-612.
ABSTRACT | FULL TEXT  

Antineoplastic Effect and Toxicity of 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 in Athymic Mice With Y-79 Human Retinoblastoma Tumors
Sabet et al.
Arch Ophthalmol 1999;117:365-370.
ABSTRACT | FULL TEXT  

A New Era for the Treatment of Retinoblastoma
Ferris and Chew
Arch Ophthalmol 1996;114:1412-1412.
ABSTRACT